NIH supports discovery of in vivo chemical probes for novel brain targets, with applicants expected to have validated starting compounds and bioassays; clinical trials are not allowed.
Funder: National Institutes of Health
Due Dates: February 5, 2027 (New) | March 5, 2027 (Resubmission / Revision; final deadline)
Funding Amounts: No budget cap; requests must reflect project needs, for up to 5 years
Summary: Supports discovery of small-molecule in vivo chemical probes for novel nervous-system targets and brain disease mechanisms.
Key Information: Applicants must already have validated starting compounds and bioassays; clinical trials and therapeutic discovery are not allowed.
This NIH R01 program supports the discovery and development of novel small-molecule chemical probes that modulate biological targets and enable mechanistic studies in animals. Participating institutes are the National Institute on Aging (NIA), National Eye Institute (NEI), National Institute on Drug Abuse (NIDA), and National Institute of Mental Health (NIMH). Projects should advance understanding of biological processes relevant to these institutes and discover or validate targets that inform studies of brain disease mechanisms.
The program emphasizes integrated biology and chemistry research using iterative structure-activity relationship studies to optimize existing validated hits. Work may include cellular assays, physicochemical characterization, pharmacokinetics, and in vivo efficacy studies. The priority is developing research probes that provide new insight into disease-related targets and processes, rather than discovering drugs or advancing candidate therapeutics.